As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
Despite expanding and adding hundreds of new jobs in states like Ohio in the past year, biomanufacturing CDMO National ...
Amid ongoing speculation about how the biopharmaceutical sector will fare under Donald Trump's second presidency, the ...
These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
LinkedIn likes have landed drugmakers in trouble once again. AstraZeneca—a repeat offender—and GSK were the subjects of the ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
ViiV Healthcare wants people to go deep when talking about HIV rather than merely skimming the surface of the experience of ...
Taiwan-headquartered PharmaEssentia has tapped Joseph Horvat as its new global chief commercial officer as it looks to boost ...
AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. | AstraZeneca has ...